Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6068477 | The Journal of Allergy and Clinical Immunology: In Practice | 2015 | 5 Pages |
Abstract
Recommendations concerning stopping VIT: For patients without any of the identified risk factors, VIT should be continued for 5 rather than 3 years. In patients with definite risk factors, a longer duration of VIT has to be discussed before stopping it. In mast cell disorders, VIT for life is recommended. Because of the residual risk of SARs after VIT, all patients are advised to carry an epinephrine autoinjector indefinitely and to continue to take measures to avoid Hymenoptera stings.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ulrich R. MD, Johannes MD, PhD,